Pdl Biopharma Inc (PDLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
Cash Flows From Operating Activities | |||||
Net Income | N/A | -70,691 | -68,859 | 110,701 | 63,659 |
Depreciation Amortization | N/A | 17,409 | 27,136 | 38,093 | 22,055 |
Income taxes - deferred | N/A | -10,617 | 13,846 | 39,172 | -11,463 |
Accounts receivable | N/A | 8,195 | 9,349 | 9,608 | -40,120 |
Accounts payable and accrued liabilities | N/A | 4,191 | -6,642 | 10,840 | 6,621 |
Other Working Capital | N/A | -9,761 | -23,218 | 20,866 | -13,892 |
Other Operating Activity | 0 | 28,831 | 34,963 | -188,656 | 74,858 |
Operating Cash Flow | $N/A | $-32,443 | $-13,425 | $40,624 | $101,718 |
Cash Flows From Investing Activities | |||||
Change In Deposits | N/A | N/A | N/A | 75,000 | -84,010 |
PPE Investments | N/A | -763 | -4,523 | -1,297 | -25 |
Net Acquisitions | N/A | N/A | N/A | N/A | -109,938 |
Purchase Of Investment | N/A | -60,000 | N/A | -23,213 | -22,952 |
Sale Of Investment | N/A | N/A | 4,116 | 39,956 | 4,680 |
Purchase Sale Intangibles | N/A | 82,572 | 57,969 | 107,253 | 13,082 |
Other Investing Activity | 0 | 82,572 | 57,111 | 368,441 | 67,735 |
Investing Cash Flow | $N/A | $21,809 | $56,704 | $458,887 | $-144,510 |
Cash Flows From Financing Activities | |||||
Debt Issued | N/A | N/A | N/A | N/A | 150,000 |
Debt Repayment | N/A | -97,889 | -126,447 | N/A | -120,000 |
Common Stock Repurchased | N/A | -86,898 | -49,109 | -30,000 | N/A |
Dividend Paid | N/A | -9 | -48 | -222 | -16,583 |
Other Financing Activity | 0 | -5,709 | -351 | -89,177 | -42,354 |
Financing Cash Flow | $N/A | $-190,505 | $-175,955 | $-119,399 | $-28,937 |
Beginning Cash Position | N/A | 394,590 | 527,266 | 147,154 | 218,883 |
End Cash Position | N/A | 193,451 | 394,590 | 527,266 | 147,154 |
Net Cash Flow | $N/A | $-201,139 | $-132,676 | $380,112 | $-71,729 |
Free Cash Flow | |||||
Operating Cash Flow | N/A | -32,443 | -13,425 | 40,624 | 101,718 |
Capital Expenditure | N/A | -763 | -4,523 | -1,297 | -25 |
Free Cash Flow | 0 | -33,206 | -17,948 | 39,327 | 101,693 |